Nonmedical Use of Prescription Drugs and Sexual Risk Behaviors

Heather B. Clayton, PhD, MPH, ^a Richard Lowry, MD, MS, ^a Euna August, PhD, MPH, MCHES, ^b Sherry Everett Jones, PhD, MPH, JD^a

BACKGROUND: Substance use is associated with sexual risk behaviors among youth, but little is known about whether nonmedical prescription drug use, an increasingly common behavior, is associated with sexual risk behaviors.

METHODS: Data from the 2011 and 2013 national Youth Risk Behavior Surveys, crosssectional surveys conducted among nationally representative samples of students in grades 9 to 12 were combined (*n* = 29 008) to examine the association between ever taking prescription drugs without a doctor's prescription and sexual risk behaviors (ever having sexual intercourse, current sexual activity, lifetime number of sexual partners, condom use, and alcohol or drug use before last sexual intercourse). Using logistic regression models (adjusted for sex, race/ethnicity, grade, ever injection drug use, and use of alcohol, marijuana, heroin, cocaine, methamphetamines, ecstasy, and inhalants), we estimated adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs).

RESULTS: Nonmedical use of prescription drugs (NMUPD) was associated with ever having sexual intercourse (aPR 1.16 [95% CI 1.11–1.22]), being currently sexually active (1.26 [1.20–1.33]), having ≥4 lifetime sexual partners (1.45 [1.34–1.57]), drinking alcohol or using drugs before last sexual intercourse (1.32 [1.17–1.48]), and not using a condom at last sexual intercourse (1.14 [1.05–1.23]). As the frequency of NMUPD increased, the association between NMUPD and each of the sexual risk behaviors increased in strength, suggesting a dose–response relationship.

CONCLUSIONS: NMUPD is associated with sexual behaviors that put high school students at risk for sexually transmitted infections. These findings can be used to inform clinical and school-based interventions developed to reduce drug use and sexually transmitted infections.

abstract

WHAT'S KNOWN ON THIS SUBJECT: Nonmedical prescription drug use among youth is associated with negative outcomes such as decreased academic performance, delinquency, and other substance use, but no nationally representative studies have examined the association between nonmedical prescription drug use and sexual risk behaviors.

WHAT THIS STUDY ADDS: Using nationally representative data, this study found an independent association between nonmedical prescription drug use and sexual risk behaviors among high school students, as well as a dose-response relationship in the association between frequency of use and sexual risk behaviors.

To cite: Clayton HB, Lowry R, August E, et al. Nonmedical Use of Prescription Drugs and Sexual Risk Behaviors. *Pediatrics*. 2016;137(1):e20152480

Divisions of ^aAdolescent and School Health, and ^bHIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

Dr Clayton conceptualized and designed the study, conducted the analysis, and drafted the initial manuscript; Dr Lowry participated in the analysis; Drs Lowry, August, and Everett Jones assisted with the conceptualization of the study and critically reviewed and revised drafts of the manuscript; and all authors approved the final manuscript as submitted. Dr Clayton had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This is a work product of the US government.

DOI: 10.1542/peds.2015-2480

Accepted for publication Oct 21, 2015

FREE

Nonmedical use of prescription drugs (NMUPD) is an important public health issue in the United States. Since 1999, drug overdose deaths involving opioid analgesics have increased, and in 2011, misuse or abuse of pharmaceuticals accounted for 1.4 million emergency department visits.^{1,2} Two national studies estimate that the lifetime prevalence of NMUPD among 9th- to 12th-grade students is 17.8%, and 19.9% among 12th-grade students.^{3,4} Studies suggest that NMUPD among youth is associated with negative outcomes such as decreased academic performance, delinquency, dropping out of school, and other substance use.5-8

Studies conducted among adolescents have identified an association between substance use (eg, alcohol, marijuana, cocaine, and heroin) and sexual risk behaviors (SRBs) (eg, ever having sexual intercourse, having multiple sexual partners, not using a condom at last intercourse, and pregnancy before age 15 years), but there is a dearth of information on the association between NMUPD and SRBs among adolescents.⁹⁻¹⁷ The few studies that exist focused on special populations such as homeless youth or were conducted in small geographic or clinical settings.^{17–19} One such study surveyed sexually active adolescents and young adults aged 14 to 20 years in an emergency department setting and observed an association between each class of prescription drugs (stimulants, opioids, and sedatives) and SRBs.¹⁷ Adolescents who used >1 class of prescription drugs were significantly more likely to report inconsistent condom use, multiple sexual partners, and substance use before sexual intercourse.¹⁷ Another study, conducted among homeless youth in Los Angeles, observed an association between current prescription drug misuse and unprotected anal or vaginal sex at last sexual intercourse.¹⁹ Additionally, a

study in Michigan among students in grades 7 through 12 found an association between sexual activity and use of prescription drugs for sensation seeking.¹⁸ The limited studies on NMUPD and SRBs among adult populations have found an association between NMUPD and SRBs.^{20–22}

This study used nationally representative data to address the research gap in the possible association between NMUPD and SRBs among high school students in the United States. Our primary objectives were to (1) determine if NMUPD is independently associated with SRBs and (2) explore an association by demographic subgroups (eg, sex, race/ethnicity, grade).

METHODS

Study Population

The Centers for Disease Control and Prevention's (CDC) cross-sectional national school-based Youth Risk Behavior Survey (YRBS) has been conducted biennially since 1991. Each national YRBS uses a similar independent 3-stage cluster sample design to obtain a nationally representative sample of public and private school students in grades 9 to 12 in the 50 states and the District of Columbia.²³ Data from the 2011 and 2013 cycles were combined for this analysis to provide sufficient sample size to conduct subgroup analyses of SRBs among students engaging in NMUPD.

Student participation in the YRBS is anonymous and voluntary, and the YRBS is conducted in accordance with local parental permission procedures. YRBS participants complete a self-administered questionnaire during a regular class period and record their responses on a computer-scannable questionnaire booklet or answer sheet. For 2011 and 2013, school response rates were 81% and 77%, respectively; student response rates were 87% and 88%; and overall response rates (product of the school and student response rates for each year) were 71% and 68%. The sample size was 15 425 for 2011 and 13 583 for 2013. The data were weighted to adjust for school and student nonresponse and oversampling of black and Hispanic students. Missing data were not imputed. Details of the YRBS sampling strategies have been reported elsewhere.^{3,23} The national YRBS was reviewed and approved by an institutional review board at the CDC.

Measures

NMUPD was measured by the question, "During your life, how many times have you taken a prescription drug (such as OxyContin, Percocet, Vicodin, codeine, Adderall, Ritalin, or Xanax) without a doctor's prescription?" Response options included 0, 1 or 2, 3 to 9, 10 to 19, 20 to 39, and \geq 40 times. Lifetime use was defined as taking prescription drugs without a doctor's prescription 0 versus \geq 1 times; frequency of use was defined as 0, 1 or 2, 3 to 19, and ≥ 20 times. We evaluated the association between lifetime and frequency of NMUPD and 5 SRBs: (1) ever had sexual intercourse (question: "Have you ever had sexual intercourse"); (2) \geq 4 lifetime sexual partners (question: "During your life, with how many people have you had sexual intercourse?"); (3) currently sexually active (question: "During the past 3 months, with how many people did you have sexual intercourse?"); (4) did not use a condom at last sexual intercourse (question: "The last time you had sexual intercourse, did you or your partner use a condom?"); and (5) drank alcohol or used drugs before last sexual intercourse (question: "Did you drink alcohol or use drugs before you had sexual intercourse the last time?"). Questions without

a dichotomous response option were collapsed into 2 categories, 0 versus \geq 1. Sexual intercourse with \geq 4 people during lifetime was used as the cutoff point, as it is the classification used by CDC in prevalence reports.³ Analyses included students who were non-Hispanic black ("black"), non-Hispanic white ("white"), Hispanic (who might be of any race), and from other racial/ethnic groups, but the results for other racial/ethnic groups are not presented, as the numbers were too small for meaningful interpretation.

The psychometric properties of the majority of YRBS questions have been assessed.²⁴ Although reliability data are not available for the relatively new questions focused on NMUPD, condom use at last sexual intercourse, and using alcohol or drugs at last sexual intercourse, the majority of items assessing substance use and sexual behaviors have demonstrated substantial test-retest reliability.

Data Analysis

The association between demographic and other substance use variables with lifetime NMUPD was explored by calculating unadjusted prevalence ratios (PRs) and corresponding 95% confidence intervals (CIs) using logistic regression. Prevalence ratios are appropriate estimates for studies using cross-sectional data, particularly for behaviors that are not considered to be rare.^{25,26} Logistic regression was used to calculate adjusted prevalence ratios (aPRs) and 95% CIs for the association between NMUPD and each of the SRBs. In addition to the independent NMUPD variable, models included the following variables as potential confounders: sex, race/ethnicity, grade, injection drug use (IDU), and use of alcohol, marijuana, cocaine, heroin, methamphetamines, inhalants, and ecstasy. Analyses for

students who did not use a condom at last intercourse and drank alcohol or used drugs before last sexual intercourse were restricted to students who were currently sexually active, whereas all other models included the full sample. To ensure that potential associations between NMUPD and \geq 4 lifetime sexual partners or current sexual activity were not confounded by ever having had sexual intercourse, a sensitivity analysis was conducted, whereby models were restricted to those who had ever had sexual intercourse. Because findings were consistent with models that included the full sample (data not shown), only full-sample models for these 2 variables are reported. To examine the independent contribution of NMUPD in the context of multisubstance use, substance use behaviors were operationalized into a composite variable (0 substances used; 1 substance used, but no NMUPD; 2 substances used, but no NMUPD; 3 substances used, but no NMUPD [referent group]; or 3 substances used plus NMUPD). Substances included in this composite variable were alcohol, marijuana, and ≥ 1 other illegal drug (cocaine, heroin, ecstasy, inhalants, or methamphetamines). IDU was not included in the composite variable because it is considered a method of drug use; however, models using this composite variable were adjusted for IDU. A small proportion of students in the NMUPD group (2.8% of the total NMUPD group) had no other substance use behaviors and thus were excluded as a category in the composite variable because of sparse data. Finally, potential interactions between exposures of interest (ie, NMUPD and the composite multisubstance use variable) and demographic characteristics for each of the SRBs were assessed. When meaningful, stratified analyses are presented.

The inclusion of other substance use behaviors in the logistic regression models was necessary, as researchers have found that adolescents and young adults who report NMUPD are also more likely to use other substances.²⁷⁻²⁹ Furthermore, IDU is an important behavioral covariate, as it has been associated with HIV infection and SRBs and may be related to NMUPD: NMUPD has been implicated as a gateway behavior for later IDU.^{29–31} However, adjusting for highly correlated variables introduced a concern for multicollinearity in our models. Therefore, we assessed multicollinearity by calculating the variance inflation factor for each model and did not observe values that were outside of an acceptable range.

To account for the complex sample design of the survey, we conducted all analyses using SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, NC).

RESULTS

The percentages of male and female students in the sample were approximately equal (Table 1). Most students were white (56.3%), followed by Hispanic (20.5%) and black (14.2%). Students were fairly evenly distributed across grades 9 to 12. The most common substances used were alcohol (68.6%) and marijuana (40.3%); fewer students used inhalants (10.2%), ecstasy (7.4%), cocaine (6.2%), methamphetamines (3.5%), or heroin (2.6%). IDU was reported by 2.0%of students. The overall prevalence of NMUPD was 19.3%. Compared with white students, NMUPD was significantly less common among black students (PR 0.67 [95% CI 0.59–0.77]) and was less common among 9th-grade than 10th-grade (1.22 [1.05-1.42]), 11th-grade (1.52 [1.35–1.72]), and 12th-grade (1.62

TABLE 1 Prevalence Estimates and PRs for NMUPD by Demographic Characteristics and Substance
Use Among US High School Students, Youth Risk Behavior Surveillance System, 2011 to 2013

Characteristic	Total Sample		escription Drug or's Prescriptio	
	n (%)ª	n (%)ª	PR	95% CI
Total	29008 (100)	5373 (19.3)		
Sex				
Female	14 329 (49.2)	2382 (18.5)	Referent	
Male	14 606 (50.8)	2718 (20.0)	1.08	1.00-1.17
Race/ethnicity				
White ^b	11 620 (56.3)	725 (20.9)	Referent	
Black ^b	5760 (14.2)	2419 (14.1)	0.67	0.59-0.77
Hispanic	8022 (20.5)	1388 (19.3)	0.92	0.82-1.03
Grade				
9	7362 (27.5)	989 (14.5)	Referent	
10	6845 (25.8)	1154 (17.8)	1.22	1.05-1.42
11	7317 (23.9)	1400 (22.1)	1.52	1.35-1.72
12	7256 (22.9)	1522 (23.5)	1.62	1.44-1.81
Ever drank alcohol				
No	8342 (31.4)	276 (3.2)	Referent	
Yes	18930 (68.6)	4636 (26.7)	8.30	6.95-9.92
Ever used marijuana				
No	16 165 (59.7)	888 (5.7)	Referent	
Yes	12004 (40.3)	4065 (38.9)	6.82	6.12-7.59
Ever used inhalants				
No	25073 (89.8)	3565 (15.0)	Referent	
Yes	2852 (10.2)	1481 (57.6)	3.84	3.56-4.13
Ever used ecstasy				
No	25 457 (92.6)	3481 (14.8)	Referent	
Yes	2167 (7.4)	1516 (75.4)	5.08	4.72-5.47
Ever used cocaine				
No	26763 (93.8)	3789 (15.3)	Referent	
Yes	1832 (6.2)	1271 (77.8)	5.08	4.65-5.54
Ever used methamphetamines		· · · ·		
No	27 307 (96.4)	4299 (17.1)	Referent	
Yes	983 (3.5)	749 (82.1)	4.80	4.43-5.19
Ever used heroin				
No	26612 (97.4)	4458 (17.8)	Referent	
Yes	712 (2.6)	535 (80.8)	4.53	4.17-4.93
Ever injected any illegal drug	,			
No	26831 (98.0)	4519 (18.1)	Referent	
Yes	588 (2.0)	440 (80.9)	4.48	4.16-4.82

^a Sample n is unweighted; percentage is weighted.

^b Non-Hispanic.

[1.43–1.82]) students. NMUPD was most strongly associated with lifetime use of alcohol (8.30 [6.95–9.92]), marijuana (6.82 [6.12–7.59]), cocaine (5.08 [4.65–5.54]), and ecstasy (5.08 [4.72–5.47]), but was associated with each substance examined.

Students engaging in NMUPD, compared with students not engaging in NMUPD, had a higher prevalence of having had sexual intercourse (76.6% vs 39.9%; aPR 1.16 [95% CI 1.11– 1.22]), \geq 4 lifetime sexual partners (35.8% vs 10.1%; 1.45 [1.34–1.57]), and current sexual activity (61.2% vs 27.2%; 1.26 [1.20–1.33]). Among students who were currently sexually active, students engaging in NMUPD, compared with students not engaging in NMUPD, had a higher prevalence of not using a condom at last sexual intercourse (48.2% vs 35.8%; aPR 1.14 [1.05–1.23]) and using alcohol or drugs before last sexual intercourse (38.0% vs 14.0%; 1.32 [1.17–1.48]) (Table 2). Because of a significant interaction between NMUPD and sex and race/ ethnicity observed in models of SRBs,

we performed stratified analyses for NMUPD by these subgroups. Among male students, a significant association was observed between NMUPD and each SRB (aPR 1.17-1.32). Among female students, for all but 1 SRB (not using a condom at last sexual intercourse), a significant association was observed between NMUPD and SRBs (aPR 1.16-1.60). Among white students, NMUPD was significantly associated with all SRBs (aPR 1.15-1.50), but among black students, NMUPD was associated only with using alcohol or drugs before last sexual intercourse (aPR 1.50 [95% CI 1.24-1.81]). Among Hispanic students, for all but 1 SRB (did not use a condom at last sexual intercourse), a significant association was observed between NMUPD and SRBs (aPR 1.10-1.47).

Frequency of NMUPD was associated with SRBs (Table 3). After adjustment for covariates, the risk of having had sexual intercourse, having ≥ 4 lifetime sexual partners, current sexual activity, not using a condom at last sexual intercourse, and using alcohol or drugs before last sexual intercourse all increased as the frequency of NMUPD increased (*P* value for trend \leq .0001).

For each SRB except condom use at last sexual intercourse, associations between NMUPD and SRBs were observed when we examined level of multisubstance use (ie, composite substance use) (Table 4). Students who used 3 substances plus NMUPD were more likely to have had sexual intercourse (aPR 1.14 [95% CI 1.08–1.21]), have had \geq 4 lifetime sexual partners (1.61 [1.41-1.84]), be currently sexually active (1.32 [1.21-1.44]), and have used alcohol or drugs before last sexual intercourse (1.57 [1.28–1.92]) than students who used \geq 3 substances (ie, alcohol, marijuana, and ≥ 1 other illicit drug) but did not engage in NMUPD. Interactions between sex and the multisubstance use composite variable were observed

Characteristic Ever Had Sexual Intercourse Had \geq Lifeti n (%)° aPR 95% Cl n (%)° Ever took prescription n (%)° aPR 95% Cl n (%)° Ever took prescription n (%)° aPR 95% Cl n (%)° fever took prescription drugs without a doctor's prescription (NUUPD) ^d 9282 (39.9) - Referent 2554 (10.1) No 9282 (39.9) - Referent 2554 (10.1) 1753 (35.8) No 3770 (76.6) 1.16 1.11-1.22 1753 (35.8) Sex ^e - Referent 945 (8.2) Female - Referent 945 (8.2) No NMUPD 4490 (39.0) - Referent 158 (12.0) Male - 1.16 1.10-1.25 685 (33.7) Male - 7769 (40.9) - 1.17 No NMUPD 2073 (77.9) 1.17 1.09-1.25 1063 (37.8) Race/ethnicity ^f White ⁸ - Referent 653 (74) Ves NMUPD 1824 (75.3) 1.21 1.13-1.29 804 (34.5)	Had ≥4 Lifetime Sexual Partners <i>n</i> (%)° aPR 95% CI 2554 (10.1) — Referent 1753 (35.8) 1.45 1.34–1.57 945 (8.2) — Referent 685 (33.7) 1.60 1.41–1.80	al Partners 95% Cl Referent 1.34-1.57 Deferent	Currently Sexually Active ^a n (%)° aPR 95%	exually A	ctive ^a	Did Not Use Condom at last	e Condor	n at last	llsed Alcohol or Drugs Before Last	or Drugs B	
n (%)° a PR 95% Cl took prescription s without a doctor's 9282 (39.9) - Referent 2 s without a doctor's 9282 (39.9) - Referent 2 2 s without a doctor's 9282 (39.9) - Referent 2 2 s without a doctor's 3770 (76.6) 1.16 1.11-1.22 1 ande 4490 (39.0) - Referent 2 No NMUPD 1687 (75.2) 1.16 1.10-1.23 1 No NMUPD 4769 (40.9) - Referent 1 Yes NMUPD 2073 (77.9) 1.17 1.09-1.25 1 No NWUPD 2073 (77.9) 1.17 1.09-1.25 1 Yes NNUPD 2073 (77.9) 1.17 1.09-1.25 1 No NWUPD 1824 (75.5) 1.21 1.13-1.29 1		95% Cl Referent 1.34–1.57	n (%) ^c			Inte	Intercourse ^b		Sexua	Sexual Intercourse ^b	etore Last ie ^b
took prescription s without a doctor's s without a doctor's s sithout a doctor's a 3770 (76.6) 1.16 1.11-1.22 1 a 1.11-1.22 1 No NMUPD 4490 (39.0) Referent Yes NMUPD 1687 (75.2) 1.16 1.10-1.23 1 No NMUPD 4769 (40.9) Referent Yes NMUPD 2073 (77.9) 1.17 1.09-1.25 1 Yes NMUPD 3128 (35.3) Referent No NMUPD 3128 (35.3) Referent Yes NMUPD 1824 (76.5) 1.21 1.13-1.29 a Yes NMUPD 3048		Referent 1.34–1.57 Beferent		aPR	95% CI	n (%) c	aPR	95% CI	n (%) ^c	aPR	95% CI
9282 (39.9) Referent 2 s 3770 (76.6) 1.16 1.11-1.22 1 male 4490 (39.0) Referent 2 No NMUPD 4490 (39.0) Referent 1 Yes NMUPD 1687 (75.2) 1.16 1.10-1.23 1 No NMUPD 1687 (75.2) 1.16 1.10-1.23 1 Yes NMUPD 2073 (77.9) 1.17 1.09-1.25 1 Yes NMUPD 2073 (77.9) 1.17 1.09-1.25 1 No NMUPD 2073 (77.9) 1.17 1.09-1.25 1 Yes NMUPD 1824 (76.5) 1.21 1.15-1.29 1 No NMUPD 1824 (76.5) 1.21 1.15-1.29 1		Referent 1.34–1.57 Beferent									
s 3770 (76.5) 1.16 1.11–1.22 1 male 1.11–1.22 1 No NMUPD 4490 (39.0) – Referent 1 Yes NMUPD 1687 (75.2) 1.16 1.10–1.23 (ale 1.10–1.23 (No NMUPD 4769 (40.9) – Referent 1 Yes NMUPD 2073 (77.9) 1.17 1.09–1.25 1 Yes NMUPD 1824 (76.5) 1.21 1.13–1.29 t Yes NMUPD 1824 (76.5) 1.21 1.13–1.29 t		1.34–1.57 Referent	6410 (27.2)		Referent	2288 (35.8)		Referent	921 (14.0)		Referent
male No NMUPD 4490 (39.0) Referent Yes NMUPD 1687 (75.2) 1.16 1.10-1.23 (1.10-1.23 (1.10) No NMUPD 4769 (40.9) Referent 1 Yes NMUPD 2073 (77.9) 1.17 1.09-1.25 1 Yes NMUPD 3728 (35.3) Referent Yes NMUPD 1824 (76.5) 1.21 1.13-1.29 1 Jock Jack		Rafarant	2976 (61.2)	1.26	1.20–1.33	1401 (48.2)	1.14	1.05-1.23	1148 (38.0)	1.32	1.17-1.48
0 4490 (39.0) Referent 1 1687 (75.2) 1.16 1.10-1.23 (1 4769 (40.9) Referent 1 1 2073 (77.9) 1.17 1.09-1.25 1 1 2073 (77.9) 1.17 1.09-1.25 1 1 3128 (35.3) Referent 1 1 1824 (76.5) 1.21 1.13-1.29 1	. –	Rafarant							(0.00)		
0 4490 (39.0) Referent 1687 (75.2) 1.16 1.10-1.23 (0 4769 (40.9) Referent 1 1 2073 (77.9) 1.17 1.09-1.25 1 0 3128 (35.3) Referent 1 1 1824 (76.5) 1.21 1.13-1.29 4	. –	Rafarant									
D 1687 (75.2) 1.16 1.10-1.23 0 0 4769 (40.9) Referent 1 0 2073 (77.9) 1.17 1.09-1.25 1 0 3128 (35.3) Referent 1 1 1824 (76.5) 1.21 1.13-1.29 4	-		3291 (28.3)		Referent	1426 (42.4)		Referent	425 (12.7)		Referent
0 4769 (40.9) Referent 1 D 2073 (77.9) 1.17 1.09-1.25 1 0 3128 (35.3) Referent 1 1824 (76.5) 1.21 1.13-1.29		1.41-1.80	1358 (61.8)	1.26	1.18-1.35	726 (55.4)	1.11	1.00-1.23	422 (31.2)	1.39	1.15-1.67
0 4769 (40.9) Referent 1 D 2073 (77.9) 1.17 1.09-1.25 1 0 3128 (35.3) Referent 0 1824 (76.5) 1.21 1.13-1.29 4											
D 2073 (77.9) 1.17 1.09–1.25 1 3128 (35.3) — Referent D 1824 (76.5) 1.21 1.13–1.29	98 (12.0)	Referent	3106 (26.0)		Referent	858 (28.3)		Referent	492 (15.4)		Referent
0 3128 (35.3) — Referent D 1824 (76.5) 1.21 1.13–1.29	63 (37.8) 1.32	1.20-1.45	1609 (60.6)	1.26	1.17-1.37	669 (41.4)	1.19	1.04-1.36	721 (44.4)	1.27	1.12-1.44
MUPD 3128 (35.3) — Referent IMUPD 1824 (76.5) 1.21 1.13–1.29											
MUPD 31.20 (35.3) — KERTERIL MUPD 1824 (76.5) 1.21 1.13—1.29		Dofonoat	12 101 0000		Defenset	12 027 000		Dafawat	10 217 002		Dofensat
1.13–1.29 IS24 (/6.3) 1.21 1.13–1.29	• •		(1.42) U022				;			;	
Black	UC.I (C.4C) 4(1.00.1	146/ (61./)	l.0.	04.1-62.1	(U. 64 A. O)	<u>c</u> l.	1.04-1.28	(R.CC) UCC	1.18	8C.I – I U.I
No NMUPD 2571 (57.1) Referent 1011 (21.9)	11 (21.9)	Referent	1807 (38.5)		Referent	572 (33.2)		Referent	271 (14.8)		Referent
Yes NMUPD 543 (81.5) 1.06 0.97-1.17 311 (46.2)	1 (46.2) 1.16	0.98-1.38	400 (62.2)	1.08	0.94-1.25	147 (41.8)	1.13	0.87-1.47	174 (42.0)	1.50	1.24-1.81
Hispanic											
No NMUPD 2573 (42.4) Referent 611 (9.3)	11 (9.3)	Referent	1722 (27.6)		Referent	650 (37.1)		Referent	248 (14.4)		Referent
Yes NMUPD 998 (76.0) 1.10 1.02–1.18 442 (34.2)	2 (34.2) 1.45	1.26-1.67	801 (61.5)	1.29	1.18-1.39	385 (50.6)	1.12	0.97-1.30	306 (39.4)	1.47	1.18-1.83

^b Among students who were currently sexually active.

 $^{\rm c}$ Sample n is unweighted; percentage is weighted.

^d Adjusted for sex, race/ethnicity, grade, alcohol, marijuana, cocaine, heroin, methamphetamines, inhalants, ecstasy, and IDU. ^e Adjusted for race/ethnicity, grade, alcohol, marijuana, cocaine, heroin, methamphetamines, inhalants, ecstacy, and IDU. ^f Adjusted for sex, grade, alcohol, marijuana, cocaine, heroin, methamphetamines, inhalants, ecstasy, and IDU. ^g Non-Hispanic.

for having had sexual intercourse and for having ≥ 4 lifetime sexual partners (data not shown). Although the magnitude of the association between multisubstance use with NMUPD and these SRBs differed by sex, the direction of the association remained the same, and the associations were significant among both female and male students. Significant interactions also were observed for race/ethnicity and multisubstance use for having had sexual intercourse, having ≥ 4 lifetime sexual partners, and being currently sexual active (data not shown). Multisubstance use with NMUPD was not independently associated with having had sexual intercourse or being currently sexually active among black students; however, the direction and significance of the associations remained for white and Hispanic students for all 3 SRBs. Significant interactions were observed for multisubstance use with NMUPD and grade for having had sexual intercourse, having ≥ 4 lifetime sexual partners, and being currently sexual active (data not shown). When we stratified by grade, multisubstance use with NMUPD was associated with having ≥ 4 lifetime sexual partners or current sexual activity among 10th-, 11th-, and 12th-grade students and having had sexual intercourse among 11th- and 12th-grade students.

DISCUSSION

This study found that nearly 1 in 5 US high school students engaged in NMUPD in his or her lifetime, and this behavior was positively associated with SRBs that increase the risk for pregnancy and contribute to the burden of HIV and sexually transmitted infections (STIs) among high school students: having had sexual intercourse, having ≥ 4 lifetime sexual partners, being currently sexual active, not using a condom at last sexual intercourse,

1	i
(2
(2
6	5

TABLE 3 Association Between Frequency of NMUPD and Sexual Risk	tion Between Fr	requency .	of NMUPD an	d Sexual Rish	<pre>< Factors F</pre>	or STI and Hi	IV Infection, US	High Sch	ool Students,	Factors For STI and HIV Infection, US High School Students, Youth Risk Behavior Surveillance System, 2011 to 2013	avior Surv	/eillance Syste	em, 2011 to 2013		
Characteristic	Ever Had S	Ever Had Sexual Intercourse	rcourse	Had ≥4 Lifetime Sexual Partners	time Sexu;	al Partners	Currently	Currently Sexually Active ^a	Active ^a	Did Not Use Condom at Last Intercourse ^b	Use Condom ; Intercourse ^b	at Last	Used Alcohol or Drugs Before Last Sexual Intercourse ^b	lcohol or Drugs Befo Sexual Intercourse ^b	fore Last
	n (%) ^c	aPR ^d	95% CI	n (%) ^c	aPRd	95% CI	n (%) ^c	aPR ^d	95% CI	n (%) ^c	aPR ^d	95% CI	n (%) ^c	aPR ^d	95% CI
How often took prescription															
drugs without a doctor's															
prescription															
Never	9282 (39.9)		Referent	2554		Referent	6410 (27.2)		Referent	2288 (35.8)		Referent	921 (14.0)		Referent
1-2 times	1202 (66.0)	1.10	1.04-1.16	(10.1) 422 (23.4)	1.27	1.14-1.41	909 (51.4)	1.21	1.14-1.28	381 (42.4)	1.08	0.96-1.21	248 (26.7)	1.20	1.03-1.40
3-19 times	1584 (78.9)	1.19	1.11-1.28	729 (36.3)	1.50	1.35-1.67	1266 (63.3)	1.30	1.20-1.41	568 (46.5)	1.13	1.00-1.27	477 (37.2)	1.33	1.15-1.53
≥20 times	984 (88.4)	1.33	1.23-1.44	602 (53.4)	1.80	1.60-2.03	801 (72.1)	1.32	1.20-1.46	452 (57.0)	1.30	1.16-1.47	423 (51.2)	1.55	1.31-1.83
For all categories, <i>P</i> for trend < 0001.	for trend <:0001.														
$^{\rm a}$ Had sexual intercourse with \ge 1 person during the 3 mo before the survey.	urse with ≥1 perso	on during th.	ie 3 mo before ti	he survey.											
^b Among students who were currently sexually active.	ho were currently:	sexually acti	ive.												
$^{\circ}$ Sample <i>n</i> is unweighted; percentage is weighted	\$hted; percentage i	is weighted.													

Adjusted for sex, race/ethnicity, grade level, alcohol, marijuana, cocaine, heroin, methamphetamines, inhalants, ecstasy, and IDU.

Oliar acter Istic	Ever Had Sexual Intercourse	exual Inte	ercourse	Had ≥4 Lifetime Sexual Partners	ne Sexual	Partners	Currently Sexually Active ^b	Sexually	Active ^b	Did Not Use Condom at Last	Condom &	it Last	Used Alcohol or Drugs Before Last	il or Drugs E	Sefore Last
										Inte	Intercourse ^c		Sexu	Sexual Intercourse ^c	sec
	р(%) <i>и</i>	aPR ^e	95% CI	р(%) И	aPR ^e	95% CI	р(%) И	aPR ^e	95% CI	р(%) и	aPR ^e	95% CI	р(%) <i>И</i>	aPR ^e	95% CI
Lifetime substance															
use															
No substances	1185 (15.2)	0.22	0.20-0.25	241 (2.7)	0.11	0.09-0.13	723 (9.4)	0.20	0.17-0.23	222(31.3)	0.70	0.60-0.81	0		
1 substance, no	2805 (37.4)	0.51	0.47-0.55	553 (6.9)	0.26	0.22-0.32	1845 (24.3)	0.47	0.43-0.52	613 (33.0)	0.71	0.62-0.82	115 (6.7)	0.25	0.19-0.35
NMUPD															
2 substances, no	3867 (68.0)	0.87	0.83-0.93	1242 (20.2)	0.66	0.57-0.76	2827 (49.1)	06.0	0.81-0.99	1034 (36.4)	0.78	0.69-0.89	563 (19.9)	0.72	0.59-0.89
NMUPD															
≥3 substances, no NMUPD	840 (75.7)		Referent	322 (28.3)	I	Referent	605 (53.0)	I	Referent	274 (48.0)	I	Referent	180 (28.6)	I	Referent
≥3 substances, ntus NMUPD	1814 (87.8)	1.14	1.08-1.21	1005 (49.6)	1.61	1.41-1.84	1491 (73.0)	1.32	1.21–1.44	758 (52.5)	1.06	0.93-1.21	726 (48.4)	1.57	1.28-1.92

Had sexual intercourse with \geq 1 person during the 3 mo before the survey. Among students who were currently sexually active.

d Sample n is unweighted; percentage is weighted.

Sample // Is unweignteu; percentage is weignteu
 Adjusted for sex, race/ethnicity, grade, and IDU.

and using alcohol or drugs before last sexual intercourse. As the frequency of NMUPD increased, so too did the strength of the association between NMUPD and each of the SRB outcomes. Among students who used 3 substances plus NMUPD, the likelihood of having had sexual intercourse, having ≥ 4 lifetime sexual partners, being currently sexually active, and using alcohol or drugs before last sexual intercourse was higher than among students who used ≥ 3 substances but did not engage in NMUPD.

This study is the first to use nationally representative data to examine the association between NMUPD and SRBs among high school students. Our findings are consistent with other, smaller studies that have found associations between NMUPD and SRBs.¹⁷⁻²² When we investigated interactions between demographic characteristics and the association between NMUPD and SRBs, we observed significant subgroup differences among sex and racial/ ethnic subgroups, but not grade, for several SRBs. The interaction results for race/ethnicity for NMUPD and SRBs is likely due to two factors: black students have a low prevalence of NMUPD compared with white and Hispanic students and also have a higher prevalence of SRBs such as having had sex, having ≥ 4 lifetime sexual partners, and being currently sexually active.³

There are several limitations to this study. First, the NMUPD survey question does not include street names for prescription drugs or account for use of prescribed medicine in a manner not prescribed (eg, higher doses); therefore, it is possible that NMUPD use is underreported. In addition, although much of the public health attention given to NMUPD has focused on opioids, young people also abuse prescription tranquilizers, stimulants, and sedatives, and that distinction is not captured with the YRBS.^{8,17} Although the extent of underreporting or overreporting of NMUPD and SRBs cannot be determined, YRBS questions generally demonstrate good testretest reliability.²⁴ Second, YRBS data are cross-sectional. It was not possible to determine the temporal relationship between NMUPD and SRBs. Third, these data apply only to youth who attend school, and therefore are not representative of all people in this age group.³ Nationwide, in 2009, of those aged 16 to 17 years, $\sim 4\%$ were not enrolled in a high school program and had not completed high school.³²

Healthy People 2020 objectives for adolescents are aimed at improving sexual health and reducing substance abuse behaviors, including NMUPD.33 To achieve these objectives, it is important for adolescents to receive effective health education in schools, such as integrated evidenced-based concepts from alcohol and other drug use prevention efforts with HIV and other STI prevention efforts in the classroom. The Substance Abuse and Mental Health Services Administration maintains the National Registry of Evidence-Based Programs and Practices, a searchable online registry of evidence-based interventions for substance abuse interventions, with several programs that target adolescent substance abuse and

SRBs.³⁴ Drug use prevention efforts should focus on reducing opportunities for adolescents to access prescription drugs for nonmedical purposes. According to the 2014 National Survey on Drug Use and Health, a large proportion of individuals aged 12 to 17 who reported pain reliever use in the past year indicated that their most recent source for a pain reliever for nonmedical use was a friend or relative (43.1% received from a friend or relative for free, 9.4% bought from a friend or relative, 9.0% took from a friend or relative without asking), whereas 26.2% indicated that they obtained the drug from ≥ 1 doctors.³⁵ To prevent NMUPD, many states have enacted statutes that reduce "doctor shopping," require tamper-resistant prescription forms, and require patient identification before dispensing as part of statelevel prescription drug monitoring programs.³⁶ Programs also have been instituted to facilitate safe disposal of unused and expired medications.^{37,38} The American Medical Association has recommended point-of-care prescription drug monitoring programs that integrate into a physician's workflow, as well as incentives to promote continuing education among physicians on current best prescribing practices that are tailored to specific practice/population needs.³⁹ In

addition, clinicians providing care for adolescents who disclose that they are sexually active or screen positive for STIs should consider the increased risk of NMUPD (and other substance use).

CONCLUSIONS

NMUPD was associated with SRBs that increase the risk for pregnancy, STIs, and HIV infection among US high school students. To better understand the association between NMUPD and SRBs, future research should explore the associations between NMUPD and SRBs by drug class (ie, opioids, sedatives, stimulants) and investigate the temporality of the association through longitudinal research.

ABBREVIATIONS

aPR: adjusted prevalence ratio CDC: Centers for Disease Control and Prevention CI: confidence interval IDU: injection drug use NMUPD: nonmedical use of prescription drugs PR: prevalence ratio SRB: sexual risk behavior STI: sexually transmitted infection YRBS: Youth Risk Behavior Survey

Address correspondence to: Heather Breeze Clayton, PhD, MPH, Division of Adolescent and School Health, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-75, Atlanta, GA 30329. E-mail: hhc9@cdc.gov

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2016 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

REFERENCES

 Warner M, Hedegaard H, Chen L. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012. NCHS Health E-Stat, Updated December 2, 2014. Atlanta, GA: Centers for Disease Control and Prevention. Available at: www.cdc.gov/ nchs/data/hestat/drug_poisoning/ drug_poisoning.htm. Accessed August 10, 2015 Substance Abuse and Mental Health Services Administration. Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. The Dawn Report. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2013. Available at: www.samhsa.gov/data/ 2k13/DAWN127/sr127-DAWN-highlights. htm. Accessed October 26, 2015

- Centers for Disease Control and Prevention. Youth risk behavior surveillance – United States, 2013. Surveill Summ. 2014;63(4):1–168
- Miech RA, Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future: National Survey Results on Drug Use 1975-2014. Volume 1: Secondary School Students. Available at: www.monitoringthefuture. org//pubs/monographs/mtf-vol1_2014. pdf. Accessed August 10, 2015
- McCabe SE, Boyd CJ, Teter CJ. Illicit use of opioid analgesics by high school seniors. *J Subst Abuse Treat*. 2005;28(3):225–230
- Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based study. J Am Acad Child Adolesc Psychiatry. 2008;47 (7):745–754
- Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. *J Adolesc Health*. 2005;37(1):44–51
- Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. *J* Adolesc Health. 2012;51(1):6–17
- Zapata LB, Hillis SD, Marchbanks PA, Curtis KM, Lowry R. Methamphetamine use is independently associated with recent risky sexual behaviors and adolescent pregnancy. *J Sch Health.* 2008;78(12):641–648
- Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Schootman M, Cottler LB, Bierut LJ. Number of sexual partners and associations with initiation and intensity of substance use. *AIDS Behav.* 2011;15(4):869–874
- Lowry R, Holtzman D, Truman BI, Kann L, Collins JL, Kolbe LJ. Substance use and HIV-related sexual behaviors among US high school students: are

they related? *Am J Public Health*. 1994;84(7):1116–1120

- Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Schootman M, Cottler LB, Bierut LJ. Brief report: Pregnant by age 15 years and substance use initiation among US adolescent girls. *J Adolesc*. 2012;35(5):1393–1397
- Santelli JS, Robin L, Brener ND, Lowry R. Timing of alcohol and other drug use and sexual risk behaviors among unmarried adolescents and young adults. *Fam Plann Perspect*. 2001;33(5):200–205
- Valois RF, Oeltmann JE, Waller J, Hussey JR. Relationship between number of sexual intercourse partners and selected health risk behaviors among public high school adolescents. J Adolesc Health. 1999;25(5):328–335
- Jackson C, Sweeting H, Haw S. Clustering of substance use and sexual risk behaviour in adolescence: analysis of two cohort studies. *BMJ Open*. 2012;2:e000661
- Vasilenko SA, Lanza ST. Predictors of multiple sexual partners from adolescence through young adulthood. *J Adolesc Health*. 2014;55(4):491–497
- Bonar EE, Cunningham RM, Chermack ST, et al. Prescription drug misuse and sexual risk behaviors among adolescents and emerging adults. J Stud Alcohol Drugs. 2014;75(2):259–268
- Boyd CJ, Young A, Grey M, McCabe SE. Adolescents' nonmedical use of prescription medications and other problem behaviors. *J Adolesc Health*. 2009;45(6):543–550
- Rhoades H, Winetrobe H, Rice E. Prescription drug misuse among homeless youth. *Drug Alcohol Depend*. 2014;138:229–233
- Benotsch EG, Koester S, Luckman D, Martin AM, Cejka A. Non-medical use of prescription drugs and sexual risk behavior in young adults. *Addict Behav.* 2011;36(1–2):152–155
- Mateu-Gelabert P, Guarino H, Jessell L, Teper A. Injection and sexual HIV/ HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City. J Subst Abuse Treat. 2015;48(1):13–20
- 22. Wells BE, Kelly BC, Rendina HJ, Parsons JT. Prescription drug misuse and

sexual behavior among young adults. *J* Sex Res. 2015;52(6):659–668

- Brener ND, Kann L, Shanklin S, et al; Centers for Disease Control and Prevention (CDC); Centers for Disease Control and Prevention (CDC). Methodology of the Youth Risk Behavior Surveillance System—2013. MMWR Recomm Rep. 2013;62(RR-1):1–20
- Brener ND, Kann L, McManus T, Kinchen SA, Sundberg EC, Ross JG. Reliability of the 1999 youth risk behavior survey questionnaire. *J Adolesc Health*. 2002;31(4):336–342
- Behrens T, Taeger D, Wellmann J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratio and prevalence ratio. *Methods Inf Med.* 2004;43(5):505–509
- Zocchetti C, Consonni D, Bertazzi PA. Relationship between prevalence rate ratios and odds ratios in crosssectional studies. *Int J Epidemiol.* 1997;26(1):220–223
- 27. Kelly BC, Wells BE, Pawson M, LeClair A, Parsons JT. Combinations of prescription drug misuse and illicit drugs among young adults. *Addict Behav.* 2014;39(5):941–944
- McCabe SE, West BT, Schepis TS, Teter CJ. Simultaneous co-ingestion of prescription stimulants, alcohol and other drugs: a multi-cohort national study of US adolescents. *Hum Psychopharmacol.* 2015;30(1):42–51
- Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting. *Int J Drug Policy*. 2014;25(2):257–266
- Centers for Disease Control and Prevention (CDC). HIV infection and HIVassociated behaviors among injecting drug users—20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61(8):133–138
- Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002-2004 and 2008-2010. *Drug Alcohol Depend*. 2013;132(1–2):95–100
- 32. Chapman C, Laird J, Ifill N, KewalRamani A. Trends in High School

Dropout and Completion Rates in the United States: 1972-2009. NCES 2012-006. Washington, DC: National Center for Education Statistics, US Department of Education. Available at: nces.ed.gov/pubs2012/2012006.pdf. Accessed September 17, 2015

- 33. Healthy People 2020 Objectives. Washington, DC: US Department of Health and Human Services. Updated September 15, 2015. Available at: www.healthypeople.gov/2020/topicsobjectives/topic/adolescent-health/ objectives. Accessed September 17, 2015
- Substance Abuse and Mental Health Services Administration. National Registry of Evidence-Based Programs and Practices. Updated August 27,

2015. Available at: www.nrepp.samhsa. gov/. Accessed September 17, 2015

- 35. Substance Abuse and Mental Health Services Administration. Results from the 2014 National Survey on Drug Use and Health: Detailed Tables. Updated September 10, 2015. Available at: www.samhsa.gov/data/sites/default/ files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf. Accessed September 15, 2015
- 36. State Laws on Prescription Drug Misuse and Abuse. Atlanta, GA: Centers for Disease Control and Prevention. Updated April 20, 2015. Available at: www.cdc.gov/phlp/publications/ topic/prescription.html. Accessed September 20, 2015

- National Take-Back Initiative.
 Washington, DC: US Department of Justice. Available at: www. deadiversion.usdoj.gov/drug_disposal/ takeback/index.html. Accessed September 17, 2015
- 38. Disposal Act: General Public Fact Sheet. Springfield, VA: Drug Enforcement Administration. Available at: www. deadiversion.usdoj.gov/drug_disposal/ fact_sheets/disposal_public.pdf. Accessed September 17, 2015
- 39. Combating Prescription Drug Abuse and Diversion. Chicago, IL: American Medical Association. Available at: www. ama-assn.org/ama/pub/advocacy/ topics/combating-prescription-drugabuse-diversion.page. Accessed September 17, 2015